Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13).

Wicki A, Brown N, Xyrafas A, Bize V, Hawle H, Berardi S, Cmiljanović N, Cmiljanović V, Stumm M, Dimitrijević S, Herrmann R, Prêtre V, Ritschard R, Tzankov A, Hess V, Childs A, Hierro C, Rodon J, Hess D, Joerger M, von Moos R, Sessa C, Kristeleit R.

Eur J Cancer. 2018 Jun;96:6-16. doi: 10.1016/j.ejca.2018.03.012. Epub 2018 Apr 13.

PMID:
29660598
2.

PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy.

Tarantelli C, Gaudio E, Arribas AJ, Kwee I, Hillmann P, Rinaldi A, Cascione L, Spriano F, Bernasconi E, Guidetti F, Carrassa L, Pittau RB, Beaufils F, Ritschard R, Rageot D, Sele A, Dossena B, Rossi FM, Zucchetto A, Taborelli M, Gattei V, Rossi D, Stathis A, Stussi G, Broggini M, Wymann MP, Wicki A, Zucca E, Cmiljanovic V, Fabbro D, Bertoni F.

Clin Cancer Res. 2018 Jan 1;24(1):120-129. doi: 10.1158/1078-0432.CCR-17-1041. Epub 2017 Oct 24.

PMID:
29066507
3.

mTORC1/autophagy-regulated MerTK in mutant BRAFV600 melanoma with acquired resistance to BRAF inhibition.

Xue G, Kohler R, Tang F, Hynx D, Wang Y, Orso F, Prêtre V, Ritschard R, Hirschmann P, Cron P, Roloff T, Dummer R, Mandalà M, Bichet S, Genoud C, Meyer AG, Muraro MG, Spagnoli GC, Taverna D, Rüegg C, Merghoub T, Massi D, Tang H, Levesque MP, Dirnhofer S, Zippelius A, Hemmings BA, Wicki A.

Oncotarget. 2017 May 25;8(41):69204-69218. doi: 10.18632/oncotarget.18213. eCollection 2017 Sep 19.

4.

Simultaneous targeting of VEGF-receptors 2 and 3 with immunoliposomes enhances therapeutic efficacy.

Orleth A, Mamot C, Rochlitz C, Ritschard R, Alitalo K, Christofori G, Wicki A.

J Drug Target. 2016;24(1):80-9. doi: 10.3109/1061186X.2015.1056189. Epub 2015 Jul 23.

PMID:
26204325
5.

Large-scale manufacturing of GMP-compliant anti-EGFR targeted nanocarriers: production of doxorubicin-loaded anti-EGFR-immunoliposomes for a first-in-man clinical trial.

Wicki A, Ritschard R, Loesch U, Deuster S, Rochlitz C, Mamot C.

Int J Pharm. 2015 Apr 30;484(1-2):8-15. doi: 10.1016/j.ijpharm.2015.02.034. Epub 2015 Feb 18.

PMID:
25701632
6.

Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study.

Mamot C, Ritschard R, Wicki A, Stehle G, Dieterle T, Bubendorf L, Hilker C, Deuster S, Herrmann R, Rochlitz C.

Lancet Oncol. 2012 Dec;13(12):1234-41. doi: 10.1016/S1470-2045(12)70476-X. Epub 2012 Nov 13.

PMID:
23153506
7.

Immunoliposomal delivery of doxorubicin can overcome multidrug resistance mechanisms in EGFR-overexpressing tumor cells.

Mamot C, Ritschard R, Wicki A, Küng W, Schuller J, Herrmann R, Rochlitz C.

J Drug Target. 2012 Jun;20(5):422-32. doi: 10.3109/1061186X.2012.680960. Epub 2012 Apr 23.

PMID:
22519893
8.

Targeting tumor-associated endothelial cells: anti-VEGFR2 immunoliposomes mediate tumor vessel disruption and inhibit tumor growth.

Wicki A, Rochlitz C, Orleth A, Ritschard R, Albrecht I, Herrmann R, Christofori G, Mamot C.

Clin Cancer Res. 2012 Jan 15;18(2):454-64. doi: 10.1158/1078-0432.CCR-11-1102. Epub 2011 Nov 7.

9.
10.

Gene dosage by quantitative real-time PCR.

Boulay JL, Reuter J, Ritschard R, Terracciano L, Herrmann R, Rochlitz C.

Biotechniques. 1999 Aug;27(2):228-30, 232. No abstract available.

PMID:
10457820
11.
12.
13.

Solutions to practical problems in autoradiographic technique.

Hillemann HH, Ritschard RL, Schooley JC.

Trans Am Microsc Soc. 1966 Jul;85(3):463-72. No abstract available.

PMID:
5938190
14.

A LIGHT-TIGHT, DUST-FREE DRYING BOX FOR AUTORADIOGRAPHY.

HILLEMANN HH, RITSCHARD RL.

Stain Technol. 1964 Sep;39:327-8. No abstract available.

PMID:
14211204

Supplemental Content

Loading ...
Support Center